* Fortress Biotech Inc reported a quarterly adjusted loss of $1.03 per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-3.15. The mean expectation of three analysts for the quarter was for a loss of $1.73 per share. Wall Street expected results to range from $-2.60 to $-1.13 per share.
* Revenue rose 4.8% to $13.03 million from a year ago; analysts expected $14.13 million.
* Fortress Biotech Inc's reported EPS for the quarter was a loss of $1.03.
* The company reported a quarterly loss of $15.42 million.
* Fortress Biotech Inc shares had fallen by 12.0% this quarter and lost 41.5% so far this year.
FORECAST CHANGES
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Fortress Biotech Inc is $24.00 This summary was machine generated from LSEG data May 15 at 09:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.73 -1.03 Beat
Dec. 31 2023 -1.97 -1.28 Beat
Sep. 30 2023 -3.21 -0.94 Beat
Jun. 30 2023 -3.41 -3.60 Missed
Comments